Patent ID: 8877804

Claim:
A method for modulating chemokine receptors, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I wherein: R 1 is H; R 2 is substituted or unsubstituted C 1-6 alkyl; R 5 is —S—, —S(O)—, or —S(O) 2 —; R 6 is substituted or unsubstituted 1-benzofuran; R 17 is H, substituted or unsubstituted C 1-6 alkyl, halogen, substituted or unsubstituted —OC 1-6 alkyl, CN, C(O)R 19 , NR 20 R 21 or hydroxyl; R 18 is H, substituted or unsubstituted C 1-6 alkyl, halogen, substituted or unsubstituted —OC 1-6 alkyl, CN, C(O)R 22 , NR 23 R 24 or hydroxyl; R 7 is H, halogen, CN, substituted or unsubstituted —OC 1-6 alkyl, substituted or unsubstituted C 1-6 alkyl or is substituted or unsubstituted C 3-8 cycloalkyl; R 8 is H, substituted or unsubstituted C 1-6 alkyl, halogen, substituted or unsubstituted —OC 1-6 alkyl, or hydroxyl; R 19 is H, OH or substituted or unsubstituted C 1-6 alkyl; R 20 is H or substituted or unsubstituted C 1-6 alkyl; R 21 is H or substituted or unsubstituted C 1-6 alkyl; R 22 is H, OH or substituted or unsubstituted C 1-6 alkyl; R 23 is H or substituted or unsubstituted C 1-6 alkyl; R 24 is H or substituted or unsubstituted C 1-6 alkyl; and including compounds: N-{2-[(3-aminobenzyl)thio]phenyl}-1-benzofuran-2-sulfonamide; N-{2-[(3-nitrobenzyl)sulfinyl]phenyl}-1-benzofuran-2-sulfonamide; N-{2-[(3-aminobenzyl)sulfinyl]phenyl}-1-benzofuran-2-sulfonamide; N-{2-[(3-nitrobenzyl)sulfonyl]phenyl}-1-benzofuran-2-sulfonamide; and N-{2-[(3-aminobenzyl)sulfonyl]phenyl}-1-benzofuran-2-sulfonamide; and with the proviso that R 7 , R 8 , R 17 and R 18 cannot all be H at the same time; and wherein the disease treatable by such modulation is dry eye disease.